Drugs / Gene Modified T Cells
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00673829 | May 2008 → Dec 2017 | breast cancer | Roger Williams Medical Center | Suspended | No outcome recorded Stop: Business |
| Phase 1 | NCT00673322 | May 2008 → Aug 2012 | colorectal cancer | Roger Williams Medical Center | Terminated | No outcome recorded |
| Phase 1 | NCT00664196 | Apr 2008 → Dec 2017 | prostate cancer | Roger Williams Medical Center | Suspended | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT01723306 | Oct 2012 → Oct 2016 | metastatic malignant neoplasm | Roger Williams Medical Center | Suspended | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gene Modified T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01723306 ↗ |
| Action | Deplete | “so that they can attack and kill tumor cells.” NCT00673322 ↗ |
| Modality | Cell therapy | “gene-modified autologous T cells” NCT00673322 ↗ |
| Route | Intravenous | “given through a vein in the arm or a catheter” NCT00664196 ↗ |